查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球先进心臟监测设备市场 - 2023-2030
市场调查报告书
商品编码
1374877

全球先进心臟监测设备市场 - 2023-2030

Global Advanced Cardiac monitoring Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

心臟监测设备是医生/医务人员建议的微型设备，用于远距离观察患者的心臟状态。最先进的技术使设备能够检测到最轻微的潜在声音和心跳异常。这些小小的不规则和异常被称为心律不整。如果总是出现心律不整，则表示心臟有问题，需要医疗救助。

透过心臟监测设备，重要的心臟健康资讯都可以被观察、记录并立即呈现给医生，从而消除了重复访问医生办公室的需要，并允许护理部门远端处理心臟健康状况。根据设备是临时的还是永久的以及需要获取什么类型的资料，心臟监测方法可能会有所不同。

心血管疾病病例的增加、产品授权的增加、研究活动的正面成果、市场发展（包括合併、收购、产品推出、意识的提高等因素）预计将推动预测期内全球先进心臟监测设备市场的成长。此外，新产品的推出和技术进步预计也将有助于预测期内的全球市场成长。

动力学

增加产品发布和授权

产品的推出和不同监管机构的授权预计将在预测期内推动全球市场的成长。例如，2021 年 2 月，Remo Care Solutions 推出了 Remo。 Cardia 是一种远端心臟监测系统，利用人工智慧即时监测和分析患者的生命征象。此外，2021 年11 月，专注于提供创新远距生物辨识监测产品的日常医疗技术公司Biotricity Inc. 推出了Bioheart，这是一款直接面向消费者的心臟监测仪，提供了医生使用的精确持续心臟监测技术。

此外，2021 年 7 月，雅培在美国推出了可插入式心臟监视器 (ICM) Jot Dx。该技术可以远端检测个人心律不整并提高诊断精度。同样，2022 年 4 月，美敦力 (Medtronic) 推出了两种 AccuRhythm AI 演算法，旨在透过基于云端的更新在欧洲用于 LINQ II 插入式心臟监视器 (ICM)。 AccuRhythm AI 使用人工智慧 (AI) 处理 LINQ II 收集的心律事件资料，提高医疗人员获取资料的精确度，以便他们能够合理分析和治疗不规则心律。

心血管疾病病例不断增加

预计心血管疾病病例的增加将在预测期内增加对先进心臟监测设备的需求。例如，根据世界心臟基金会2023 年报告，全球心血管疾病(CVD) 死亡人数从1990 年的1,210 万人猛增至2021 年的2,050 万人，接近所有死亡人数的三分之一，并且评估的1.21 亿CVD 死亡率整体呈现成长趋势。 CVD 再次成为 2021 年全球死亡的首要原因，五分之四的 CVD 死亡发生在低收入和中等收入国家 (LMIC)。

此外，根据英国心臟基金会的《2023 年全球心臟和循环系统疾病情况说明书》，全球约有6.2 亿人患有心臟和循环系统疾病，由于生活方式的不同、人口老化和人口增长以及生存率的提高，这一数字一直在增加。心臟病和中风的发病率预计会持续上升，如果这些趋势持续下去。

此外，据估计，全球每 13 个人中就有 1 人患有心臟或循环系统疾病。全球约有三分之一的死亡是由心臟和循环系统疾病造成的，预计到 2021 年将有 2,050 万人死亡，平均每天有 56,000 人死亡，即每 1.5 秒就有 1 人死亡。同样，根据澳洲卫生和老年护理部的数据，心血管疾病导致澳洲约 27% 的伤亡，约 120 万澳洲人患有一种或多种心臟或血管疾病。

网路安全威胁与违规行为

与心臟监测设备相关的网路安全威胁的存在预计将阻碍预测期内的全球市场成长。例如，2023 年 7 月，网路安全和基础设施安全局 (CISA) 发出警报，称医疗设备公司美敦力 (Medtronic) 的心臟设备存在极端漏洞。此外，在安全更新中，这家医疗科技巨头宣称，它已经确定了一个可选的消息传递元素，如果允许，授权用户可以操纵该缺陷，从而导致心臟设备资料可能的遗漏、窃取或转换。

该公司起草了针对当前软体问题的修復方案，并分配了进一步的软体更新，以撤回讯息传递元素。此外，违反监管准则可能会导致产品召回，从而在预测期内减缓全球市场成长。例如，美国食品药物管理局 (FDA) 已向心臟监测公司 iRhythm IRTC 发出通知，指出其开发违反了 FDA 设备和标籤规范。

误报率高

预计误报的高频率也将阻碍预测期内全球市场的成长。例如，根据题为「循环：心律不整和电生理学」的文章中发表的新资料，用于追踪心律不整的植入式循环记录器(ILR) 很容易出现误报警报，ILR 是针对潜在心律不整个体的典型诊断设备，允许长期远端患者监测。文章的结论是，研究中的所有警报中有59.8% 是错误的，房性心动过速(AT)/心房颤动(AF)AT/AF (74.2%) 和心搏停止(76.8%) 警报的假阳性率较高。

此外，通常在医务室中，重症监护病房 (ICU) 患者监护仪的假心律不整警报率极高，无论其商标和费用如何。这些错误分配的警报会扰乱个人的休息，耗尽医院资源，并使医务人员对可能发生的紧急情况麻木不仁，这被称为误报疲劳。根据评估，床边监视器分配的危及生命的心电图 (ECG) 警报中有 43% 不准确，某些类型的警报甚至高达 90%。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按设备类型分類的片段
  • 按指示显示的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 增加产品发布和授权
      • 心血管疾病病例不断增加
    • 限制
      • 网路安全威胁与违规行为
      • 误报率高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 专利分析
  • 科技趋势
  • 最终用户趋势
  • SWOT分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按装置类型

  • 心电图监视器
  • 插入式心臟监测仪
  • 动态心电图监测仪
  • 事件记录器
  • 移动心臟遥测
  • 智慧型穿戴装置
  • 植入式心臟循环记录仪
  • 其他的

第 8 章：依指示

  • 心搏过缓
  • 心跳过速
  • 心房和心室颤动
  • 其他的

第 9 章：最终用户

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 学术研究机构
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Abbott
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Medtronic plc
  • Boston Scientific Corporation
  • Biotronic AG
  • Stryker
  • Microport Scientific Corporation
  • Koninklijke Philips NV
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • GE HEALTHCARE
  • Nihon Kohden

第 13 章：附录

简介目录
Product Code: MD7233

Overview

A cardiac monitoring device is a miniature device suggested by the doctor/medic to observe a patient's cardiac state from a distance, remotely. State-of-the-art technology facilitates the device to detect even the slightest potential sounds and abnormalities in the heartbeat. These small irregularities and anomalies are anointed heart arrhythmias. If the arrhythmias transpire invariably, there is an issue in the heart that requires medical assistance.

With a cardiac monitoring device, significant cardiac health information can all be observed, documented, and presented to the physician immediately eliminating the requirement for repeated visits to the medic's office and permitting the care unit to handle the cardiac health remotely. Cardiac monitoring approaches can differ based on whether the device is temporary or permanent and what sort of data needs to be apprehended.

The growing cases of cardiovascular diseases, increasing product authorizations, positive outcomes from research activities, market developments including mergers, acquisitions, product introductions, growing awareness among other factors are expected to boost the global advanced cardiac monitoring devices market growth in the forecast period. Further, the new product launches and technological advancements also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Product Launches and Authorizations

The product launches and authorizations from distinct regulatory bodies are expected to boost the global market growth during the forecast period. For instance, in February 2021, Remo Care Solutions introduced Remo. Cardia is a remote cardiac monitoring system that utilizes artificial intelligence to monitor and analyze patients' vitals in real time. Moreover, in November 2021, Biotricity Inc., an everyday medical technology corporation concentrated on providing innovative, remote biometric monitoring products, launched Bioheart, a direct-to-consumer heart monitor that presents the exact constant heart monitoring technology utilized by physicians.

Further, in July 2021 Abbott introduced Jot Dx, the insertable cardiac monitor (ICM) in the United States. This technology permits remote detection and enhanced diagnostic precision of cardiac arrhythmias in individuals. Similarly, in April 2022, Medtronic introduced two AccuRhythm AI algorithms intended to be used for LINQ II insertable cardiac monitors (ICM) via cloud-based updates in Europe. AccuRhythm AI uses artificial intelligence (AI) to heart rhythm event data gathered by LINQ II, enhancing the precision of data medics obtain so they can reasonably analyze and treat irregular heart rhythms.

Growing Cases of Cardiovascular Diseases

The growing cases of cardiovascular diseases are expected to boost the demand for advanced cardiac monitoring devices in the forecast period. For instance, according to the World Heart Foundation Report 2023, deaths from cardiovascular disease (CVD) bounced worldwide from 12.1 million in 1990 to 20.5 million in 2021, near to a third of all deaths and a general growth on the assessed 121 million CVD mortalities. Again, CVD was the top reason of death globally in 2021, with four in five CVD deaths happening in low- and middle-income nations (LMICs).

Moreover, according to the British Heart Foundation's Global Heart & Circulatory Diseases Factsheet 2023, about 620 million individuals are living with cardiac and circulatory conditions across the globe this number has been increasing owing to varying lifestyles, an aging, and growing inhabitants, and enhanced survival rates from heart attacks and strokes and is estimated to persist to increase if these trends persist.

Further, globally it is assessed that 1 in 13 individuals are living with a cardiac or circulatory disorder. Heart and circulatory conditions cause about 1 in 3 deaths worldwide, an estimated 20.5 million casualties in 2021, an average of 56,000 individuals per day, or one death every 1.5 seconds. Again, according to the Department of Health and Aged Care Government of Australia, Cardiovascular conditions cause around 27% of casualties in Australia and about 1.2 million Australians have 1 or more heart or vascular diseases.

Cybersecurity Threats and Violation of Regulations

The presence of cybersecurity threats associated with cardiac monitoring devices is expected to hamper the global market growth during the forecast period. For instance, in July 2023, The Cybersecurity and Infrastructure Security Agency (CISA) alerted of an extreme vulnerability in a cardiac device from medical device corporation Medtronic. Moreover, in a security update, the medtech giant declared that it had pinpointed an optional messaging element that, if allowed, a licensed user could manipulate the flaw, directing to the possible omission, stealing, or transformation of cardiac device data.

The corporation drafted a fix for the problem on the present software and has allocated a further software update that withdraws the messaging element. Furthermore the the violation of regulatory guidelines can cause product recalls slowing the global market growth during the forecast period. For instance, the Food and Drug Administration (FDA) has given a notice to the heart monitoring corporation iRhythm IRTC, noting that its developments enclose breaches of FDA device and labeling norms.

High Frequency of False Positive Alarms

The high frequency of false positive alarms is also expected to hamper the global market growth during the forecast period. For instance, according to new data published in an article titled "Circulation: Arrhythmia and Electrophysiology," the implantable loop recorders (ILR) employed to follow cardiac arrhythmias are liable to false positive alerts, ILRs are typical diagnostic devices for individuals with a potential arrhythmia, permitting for long-term remote patient monitoring. The article concluded that 59.8% of all alerts in the study were wrong, with elevated false-positive rates for atrial tachycardia (AT)/atrial fibrillation (AF)AT/AF (74.2%) and asystole (76.8%) alerts.

Further, typically in infirmaries, false arrhythmia alarm rates are extremely elevated in intensive care units (ICUs) patient monitors irrespective of their trademarks and expenses. These falsely allocated alarms disrupt individuals' rest, empty hospital resources, and desensitize the infirmary team to possible emergencies, anointed as false alarm fatigue. It has been assessed that 43% of life-threatening electrocardiogram (ECG) alarms allocated by bedside monitors are inaccurate, with some types of alarms being as elevated as 90%.

Segment Analysis

The global advanced cardiac monitoring devices market is segmented based on device type, indication, end-user and region.

ECG Monitors Device Type Expected to Dominate Market

With the increase in the ECG monitor product market introductions and market developments in this segment the ECG monitor device type is expected to dominate the global market in the forecast period. For instance, in May 2022, AliveCor introduced the KardiaMobile Card, a credit card-sized, tiniest personal ECG device designed to enhance health outputs and reduce the expense of cardiac therapy. A single-lead ECG of medical quality is produced in 30 seconds via the KardiaMobile Card, which fits comfortably into any wallet.

Moreover, in August 2023, Clario, a healthcare research technology corporation that provides top endpoint technology products for clinical investigations, expanded its partnership with AliveCor, the top leader in FDA-cleared personal electrocardiogram (ECG) technology. This partnership intends to allow trial participants to accumulate medical-grade six-lead ECG readings in the convenience of their residences via KardiaRx, a clinical-trial-focused app.

Geographical Penetration

Growing Cases of Cardiovascular Diseases

Owing to the increasing cases of cardiovascular disease in North America the region is estimated to dominate the global market during the forecast period. For instance, according to the Centers for Disease Control and Prevention, June 2022 update around 20.1 million adults aged 20 and older had coronary heart disease (CAD) in 2020 in the United States. It even noted that coronary heart condition is the highly typical type of heart condition in the United States.

Furthermore, the increase in market developments in this region is also contributing to the regional market growth in the forecast period. For instance, in November 2022, OMRON Healthcare, Co., Ltd., a multinational healthcare corporation, collaborated with Cardio Signal, a U.S.-established health technology corporation, aspired to get innovations in premature cardiovascular condition detection to help clinicians at the forefront of Population Health management.

Similarly, in July 2021, Nihon Kohden Digital Health Solutions Inc., the U.S. regional development associate of Nihon Kohden, completed the acquisition of 100% shares of Advanced Medical Predictive Devices, Diagnostics, and Displays, Inc., following this acquisition, Nihon Kohden's long-term intends to develop innovative healthcare monitoring devices to crack global medical issues and to deliver better future to individuals with from diverse conditions.

COVID-19 Impact Analysis

COVID-19 unexpectedly increased patient safety, prior to the COVID-19 pandemic, patient monitoring for harm and multiple strategies to avert damage were related to where the individuals were treated in the hospital. The challenges raised by the Coronavirus disease 2019 (COVID-19) pandemic to the health service globally directed to a quick transformation of infection condition protocols in-hospital.

Although the integration of technology in the clinical workplace is yet in its babyhood, it has rapidly progressed via the Gartner Hype Cycle for rising technologies and its adoption has additionally quickened after the coronavirus disease 2019 (COVID-19) pandemic and the fierce growth of telehealth. The COVID-19 pandemic has led to an acceleration in healthcare innovation, with the adoption of telemedicine taking residence nearly overnight. Additional wearable patient monitoring devices are used to help improve the availability of monitoring and therapy of patients and to support addressing the deduction of healthcare provider exposure to SARS-CoV-2, especially for people with heart disease.

By Device Type

  • ECG Monitors
  • Insertable Cardiac Monitor
  • Holter Monitor
  • Event Recorder
  • Mobile cardiac Telemetry
  • Smart Wearables
  • Implantable Cardiac Loop Recorders
  • Others

By Indication

  • Bradycardia
  • Tachycardia
  • Atrial and Ventricular Fibrillation
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers
  • Academic Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In July 2023, Biotricity Inc., a Technology-as-a-Service (TaaS) corporation functioning in the remote cardiac monitoring domain of consumer healthcare, reinforced connections with Amazon and Google. The company is extending its AI technology development in remote cardiac care, leveraging its proprietary AI technology to deliver a suite of predictive monitoring devices to improve new condition profiling, enhance patient control, and revolutionize the healthcare enterprise for disease precluding.
  • In May 2023, Abbott, obtained U.S. Food and Drug Administration (FDA) clearance for its Assert-IQ insertable cardiac monitor (ICM), offering medics a unique choice for diagnostic evaluation and long-term monitoring of individuals experiencing irregular heartbeats.
  • In January 2023, Royal Philips, a multinational leader in health technology, and Masimo, a multinational medical technology corporation, expanded their collaboration to increase individual monitoring capacities in-home telehealth applications with the Masimo W1 state-of-the-art health tracking watch. The W1 intends to merge with Philips's enterprise patient monitoring ecosystem to proffer the vanguard of telemonitoring and telehealth.

Competitive Landscape

The major global players in the market include: Abbott, Medtronic plc, Boston Scientific Corporation, Biotronic AG, Stryker, Microport Scientific Corporation, Koninklijke Philips N.V., Lepu Medical Technology (Beijing)Co., Ltd., GE HEALTHCARE, and Nihon Kohden among others.

Why Purchase the Report?

  • To visualize the global advanced cardiac monitoring devices market segmentation based on device type, indication, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of advanced cardiac monitoring devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global advanced cardiac monitoring devices market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Launches and Authorizations
      • 4.1.1.2. Growing Cases of Cardiovascular Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Cybersecurity Threats and Violation of Regulations
      • 4.1.2.2. High Frequency of False Positive Alarms
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. Technology Trend
  • 5.7. End-User Trend
  • 5.8. SWOT Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. ECG Monitors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Insertable Cardiac Monitor
  • 7.4. Holter Monitor
  • 7.5. Event Recorder
  • 7.6. Mobile cardiac Telemetry
  • 7.7. Smart Wearables
  • 7.8. Implantable Cardiac Loop Recorders
  • 7.9. Others

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Bradycardia*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Tachycardia
  • 8.4. Atrial and Ventricular Fibrillation
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Ambulatory Surgery Centers
  • 9.5. Academic Research Institutes
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Medtronic plc
  • 12.3. Boston Scientific Corporation
  • 12.4. Biotronic AG
  • 12.5. Stryker
  • 12.6. Microport Scientific Corporation
  • 12.7. Koninklijke Philips N.V.
  • 12.8. Lepu Medical Technology (Beijing) Co., Ltd.
  • 12.9. GE HEALTHCARE
  • 12.10. Nihon Kohden

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us